How much do you know about gout? Take this interesting and informative gout quiz and test your knowledge about who gout affects, what causes gout, how gout flares are triggered and gout flare prevention.

Step 1 of 10

  • According to the latest (2019) statistics, approximately how many Americans are affected by gout?

 

Mitigare® is a registered trademark of Hikma Pharmaceuticals USA Inc.

References

  1. Chen-Xu M, et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019 Jun;71(6):991–999.
  2. Go For Six. Gout Education Society website. Available at: https://gouteducation.org/patient/go-for-six/. Accessed December 12, 2019.
  3. Gout. Cleveland Clinic website. Available at: https://my.clevelandclinic.org/health/diseases/4755-gout. Accessed December 12, 2019.
  4. Choi HK, et al. Nocturnal risk of gout attacks. Arthritis Rheumatol. 2015;67(2):555–562.
  5. What is Gout? Gout Education Society website. Available at: https://gouteducation.org/what-is-gout/. Accessed December 12, 2019.
  6. Allopurinol Tablets, USP [prescribing information]. Memphis, TN: Northstar Healthcare Holdings; 2016.
  7. KRYSTEXXA® (pegloticase injection) [prescribing information]. Lake Forest, IL: Horizon Pharma Rheumatology LLC; 2016.
  8. Mitigare® (colchicine) capsules [prescribing information]. Columbus, OH: West-Ward Columbus, Inc.; 2019.
  9. Nicola Dalbeth and Keith J Petrie: It’s time to change the name of gout. The British Medical Journal Opinion/Comment and opinion from the BMJ’s international community of readers, authors, and editors. Available at: https://blogs.bmj.com/bmj/2018/02/05/nicola-dalbeth-and-keith-j-petrie-its-time-to-change-the-name-of-gout/. Accessed May 1, 2019.
  10. Higashino T, Takada T, Nakaoka H, et al. Multiple common and rare variants of ABCG2 cause gout. RMD Open. 2017;3:e000464.
  11. Chang S-J, Chen C-J, et al. ABCG2 contributes to the development of gout and hyperuricemia in a genome-wide association study. Nature/Scientific Reports. 2018;8:3137.
  12. Zhu Y et al. Prevalence of Gout and Hyperuricemia in the US General Population. The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–3141.
  13. Gout/Diagnosis & treatment. Mayo Clinic Website. Available at: https://www.mayoclinic.org/diseases-conditions/gout/diagnosis-treatment/drc-20372903. Accessed December 12, 2019.
  14. Singh JA. The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther. 2014;16:R132.
  15. Rome et al. The effects of commercially available footwear on foot pain and disability in people with gout: a pilot study. BMC Musculoskeletal Disorders. 2013;14:278–287.
  16. Stewart S et al. The effect of good and poor walking shoe characteristics on plantar pressure and gain in people with gout. Clin Biomech. 2014;29(10):1158–1163.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.